Epetraborole's Phase 3 Data Crucial for AN2 Therapeutics' Prospects AN2 Therapeutics’ lead drug candidate, epetraborole, is set for pivotal Phase 3 trial data in Q2 2025. The trial focuses on patient-reported outcomes, aligning with FDA guidance. Positive results could pave the way for regulatory discussions, solidifying the company's position in addressing refractory MAC lung disease.789